AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca, in collaboration with Parexel International, is conducting a study titled An Open-Label, Randomized, Four-Treatment, Four-Period, Single-Dose Crossover Study in Healthy Participants to Assess the Relative Bioavailability of AZD5004 in Three Solid Oral Formulations (F1, F3, F4). The study aims to evaluate the relative bioavailability of the drug AZD5004 across three different oral tablet formulations in healthy participants, which is crucial for determining the most effective formulation for future development.
The intervention being tested is AZD5004, a drug administered in three solid oral formulations (F1, F3, and F4). The study seeks to determine which formulation offers the best bioavailability, thereby optimizing the drug’s efficacy and safety profile.
This Phase 1 study employs an open-label, randomized, crossover design. Participants receive single doses of AZD5004 in different sequences across four treatment periods, with no masking involved. The primary purpose is to assess treatment efficacy.
The study began on May 22, 2025, with its primary completion date yet to be announced. The last update was submitted on June 27, 2025. These dates are essential for tracking the study’s progress and anticipating results that could impact market dynamics.
For investors, this study’s outcome could significantly influence AstraZeneca’s stock performance. Positive results may enhance the company’s competitive edge in the pharmaceutical market, potentially boosting investor confidence. The involvement of Parexel also underscores the study’s credibility and potential impact.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.